A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.

Trial Profile

A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Hepatitis A vaccine inactivated; Measles mumps and rubella virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
  • Indications Chickenpox; Hepatitis A; Measles; Mumps; Pneumococcal infections; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Nov 2011 Planned number of patients is 1220 as reported by ClinicalTrials.gov.
    • 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 11 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top